Table 2.
Percent of People with Three Chronic Illnesses Using Particular Groups of Medications, by Managed Care and Indemnity Insurance, 1997
| Comparison | ||||
|---|---|---|---|---|
| Managed Care % | Indemnity % | Unadjusted Odds Ratio (95% CI) | Adjusted Odds Ratio (95% CI) | |
| Diabetes | ||||
| 1st or 2d sulfonylureas | 42.7 | 38.2 | 1.20 (1.14–1.26) | 1.22 (1.15–1.29) |
| All noninsulin hypoglycemics* | 63.0 | 56.4 | 1.31(1.25–1.38) | 1.35 (1.28–1.44) |
| (Number) | (16,004) | (10,440) | ||
| CHF | ||||
| ACE/ARB | 48.8 | 39.5 | 1.45 (1.33–1.60) | 1.18 (1.06–1.31) |
| Carvedilol or beta-blockers | 24.6 | 16.2 | 1.68 (1.50–1.88) | 1.41(1.24–1.60) |
| (Number) | (2,875) | (5,103) | ||
| Asthma | ||||
| Asthma “controllers”* | 39.2 | 33.2 | 1.29 (1.17–1.44) | 1.40 (1.24–1.57) |
| (Number) | (7,869) | (1,981) | ||
*
All noninsulin hypoglycemics: Sulfonalyureas 1st and 2d, Metformin, Rezulin, and ACE/ARB.
Asthma “controllers” are claims for inhaled steroids, cromolyn, leukoriene, and long-acting beta-agonists.
Adjusted models are the same as in the first analyses presented in Table 1.